

SEP 25 2000

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

OLSON & HIERL, LTD 20 NORTH WACKER DRIVE 36TH FLOOR CHICAGO IL 60606 Re: Patent Term Extension Application for

U.S. Patent No. 4,949,718

Dear Mr. Hierl:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,949,718 for a period of 605 days.

While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). The communication to FDA should included sending a copy of the certificate of extension to New Drug Application and another copy of the certificate of extension to Mary Ann Holovac, who will update the Orange Book. Mary Ann's address is

CDER OIT DDMS NLRC 235 (HFD-090) 5516 Nicholson Lane Kensington, MD 20895

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Tyson

Senior Legal Advisor

Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc:

David T. Read

Re: ThermaChoiceTM Uterine Balloon Therapy System

Acting Director Regulatory Policy Staff, CDER FDA Docket No. 98E-0850

Food and Drug Administration 1451 Rockville Pike, HFD-7 Rockville, MD 20852

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO.

4,949,718

ISSUED

August 21, 1990

INVENTORS

Robert S. Neuwirth, et al.

PATENT OWNER

Gynelab Products

PRODUCT

ThermaChoice™ Uterine Balloon Therapy System

This is to certify that an application under 35 U.S.C. § 156 has been filed in the U.S. Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 4,949,718 based upon the regulatory review of the product ThermaChoice™ Uterine Balloon Therapy System by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

605 days

from September 9, 2008, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the U.S. Patent and Trademark Office to be affixed this 12th day of September 2000.

Q. Todd Dickinson

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office